Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 4067 results found since Jan 2013.

Apolipoproteins B and A1 in Ischemic Stroke Subtypes
Introduction: Elevated serum apolipoprotein B and the apolipoprotein B/A1 ratio have been associated with ischemic stroke and intracranial atherosclerotic disease. We sought to assess the relationship between serum levels of apolipoprotein B, apolipoprotein A1, and the apolipoprotein B/A1 ratio with ischemic stroke subtypes and large artery atherosclerosis location. Materials and Methods: We evaluated serum apolipoprotein B and apolipoprotein A1 levels in consecutive, statin-na ïve, adult ischemic stroke patients admitted to an academic medical center in southern India.
Source: Journal of Stroke and Cerebrovascular Diseases - February 9, 2020 Category: Neurology Authors: Rizwan Kalani, Soumya Krishnamoorthy, D. Deepa, Srinivas Gopala, Dorairaj Prabhakaran, David Tirschwell, P.N. Sylaja Source Type: research

Statin Pretreatment Might Be Associated with Decreased Myocardial Injury After Ischemic Stroke
In this study, we aimed at investigating the association between statin pretreatment and poststroke myocardial injury. Methods: Six hundred seventy-one patients diagnosed as acute ischemic stroke were enrolled. According to the histories of statin pretreatment before stroke, patients were categorized into nonstatin (n  = 474) and statin groups (n = 197), with the latter further divided into low-dosage, standard-dosage, and high-dosage subgroups according the dosages of statins.
Source: Journal of Stroke and Cerebrovascular Diseases - February 20, 2020 Category: Neurology Authors: Ke-Wu Wang, Chao Feng, Yin-Fei Wu, Jing Huang, Wen-Bo Xiao, Shu-Dong Xia Source Type: research

Controversies: Stroke Prevention in Chronic Kidney Disease
Risk of both ischemic and hemorrhagic stroke is increased in the chronic kidney disease (CKD) population, particularly in end-stage kidney disease patients. Uremic factors that contribute to stroke risk include blood pressure variability, vascular calcification, build-up of vascular toxins, chronic inflammation, platelet dysfunction and increased brain microbleeds. This paper discusses the controversial evidence for stroke prevention strategies including blood pressure control, statins, antiplatelet agents, and anticoagulation in the CKD population.
Source: Journal of Stroke and Cerebrovascular Diseases - February 25, 2021 Category: Neurology Authors: Wei Ling Lau Source Type: research

Treatment of Ischemic Stroke by Atorvastatin-Loaded PEGylated Liposome
AbstractThere is insufficient evidence on the effect of nanoparticles, particularly liposomes loaded with a statin, on acute ischemic stroke. We investigated the impact of atorvastatin-loaded PEG (polyethylene glycol) conjugated liposomes (LipoStatin) on the outcomes in rats with cerebral ischemia –reperfusion. PEGylated liposome loaded with atorvastatin was developed as a nanoparticle to specifically accumulate in an ischemic region and release the drug to ameliorate the harmful effects of the stroke. LipoStatin was administered to rats with transient middle cerebral artery occlusion throu gh the tail vein immediately a...
Source: Translational Stroke Research - January 14, 2023 Category: Neurology Source Type: research

Statin Therapy Should Not be Discontinued in Patients With Intracerebral Hemorrhage Controversies in Stroke
Source: Stroke - June 24, 2013 Category: Neurology Authors: Bustamante, A., Montaner, J. Tags: Acute Cerebral Hemorrhage, Cerebral Lacunes, Neuroprotectors, Other Stroke Treatment - Medical Controversies in Stroke Source Type: research

Continued Statin Treatment After Acute Intracranial Hemorrhage: Fighting Fire With Fire Controversies in Stroke
Source: Stroke - June 24, 2013 Category: Neurology Authors: Molina, C. A., Selim, M. H. Tags: Acute Cerebral Hemorrhage, Other Stroke Treatment - Medical Controversies in Stroke Source Type: research

Apolipoprotein E, Statins, and Risk of Intracerebral Hemorrhage Clinical Sciences
Conclusions— Statin use does not seem to attenuate the association of HC with decreased risk for nonlobar ICH. Our data support a gene-by-drug effect for lobar ICH, but larger sample sizes are needed to confirm the association before any clinical change is warranted. Clinical Trial Registration— URL: http://clinicaltrials.gov. Unique identifier: NCT00930280.
Source: Stroke - October 21, 2013 Category: Neurology Authors: Woo, D., Deka, R., Falcone, G. J., Flaherty, M. L., Haverbusch, M., Martini, S. R., Greenberg, S. M., Ayres, A. M., Sauerbeck, L., Kissela, B. M., Kleindorfer, D. O., Moomaw, C. J., Anderson, C. D., Broderick, J. P., Rosand, J., Langefeld, C. D., Woo, J. Tags: Embolic stroke Clinical Sciences Source Type: research

Atorvastatin Treatment and Carotid Plaque Morphology in First-ever Atherosclerotic Transient Ischemic Attack/Stroke: A Case–Control Study
A relationship between echolucency of carotid plaques and the consequent risk of ipsilateral ischemic stroke has been observed. An aggressive lipid-lowering therapy may increase the echogenicity of carotid plaque in patients with elevated low-density lipoprotein cholesterol levels. The aim of this study is to prospectively evaluate the long-term effect of high-dose atorvastatin on carotid plaque morphology in patients with first-ever transient ischemic attack or stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - October 21, 2014 Category: Neurology Authors: Pasquale Marchione, Claudio Vento, Manuela Morreale, Chiara Izzo, Andrea Maugeri, Federica Manuppella, Tommaso Romeo, Patrizia Giacomini Source Type: research

Infratentorial Microbleeds: Another Sign of Microangiopathy in Migraine Brief Reports
Conclusions— Migraine, notably without aura, is associated with infratentorial CMBs at older age. CMBs and infarcts co-occur more often in migraine than in controls. This supports the hypothesis of small-vessel involvement in migraine pathophysiology.
Source: Stroke - June 22, 2015 Category: Neurology Authors: Arkink, E. B., Terwindt, G. M., de Craen, A. J. M., Konishi, J., van der Grond, J., van Buchem, M. A., Ferrari, M. D., Kruit, M. C., on behalf of the PROSPER Study Group Tags: Cerebrovascular disease/stroke, Computerized tomography and Magnetic Resonance Imaging, Risk Factors for Stroke Brief Reports Source Type: research

HMG-CoA Reductase Inhibitor (Statin) Prescribing for Ischemic Stroke Patients at Hospital Discharge (P2.306)
Conclusions: Our observations suggest that neurologists may be more likely to prescribe a statin at the time of discharge for whites in group 3 (diabetics age 40-75 with LDL 70-189 without ASCVD) when compared to their black counterparts. Further research is needed to determine if racial disparities exist in discharge statin prescribing for stroke survivors.Disclosure: Dr. Albright has nothing to disclose. Dr. Vahidy has nothing to disclose. Dr. Sisson has nothing to disclose. Dr. Samai has nothing to disclose. Dr. Schluter has nothing to disclose. Dr. Martin-Schild has received personal compensation for activities with Genentech.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Albright, K., Vahidy, F., Moore, M., Samai, A., Schluter, L., Martin-Schild, S. Tags: Stroke Systems of Care Source Type: research

Prescription of Guideline-Based Medical Therapies at Discharge After Carotid Artery Stenting and Endarterectomy: An NCDR Analysis Clinical Sciences
Conclusions— US antiplatelet agent and statin discharge prescription rates were suboptimal after both CAS and CEA and varied by revascularization modality, operating physician specialty, and hospital characteristics. Improved and more uniform utilization after these procedures will be critical to the success of comprehensive stroke risk reduction efforts.
Source: Stroke - August 21, 2016 Category: Neurology Authors: Aronow, H. D., Kennedy, K. F., Wayangankar, S. A., Katzen, B. T., Schneider, P. A., Abou-Chebl, A., Rosenfield, K. A. Tags: Secondary Prevention, Cardiovascular Surgery, Stent, Cerebrovascular Disease/Stroke, Peripheral Vascular Disease Clinical Sciences Source Type: research

The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study: Rationale and Trial Protocol
The preventive effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on progression of carotid intima-media complex thickness (IMT) has been shown exclusively in nonstroke Western patients. The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study aims to determine the effect of pravastatin on carotid IMT in Japanese patients with hyperlipidemia who developed noncardioembolic ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - December 20, 2016 Category: Neurology Authors: Kazunori Toyoda, Kazuo Minematsu, Masahiro Yasaka, Yoji Nagai, Naohisa Hosomi, Hideki Origasa, Kazuo Kitagawa, Shinichiro Uchiyama, Masatoshi Koga, Masayasu Matsumoto, J-STARS Investigators Source Type: research

Exercise for stroke prevention: The neglected prescription
For over a decade, clinicians have used multimodal pharmacologic therapy for optimal stroke prevention based in part on promising results from clinical trials demonstrating the value of blood pressure and cholesterol lowering for secondary stroke prevention. Patients are typically treated with a cocktail of medications, including antithrombotic agents, antihypertensives, and statins.1
Source: Neurology - January 22, 2017 Category: Neurology Authors: Chaturvedi, S., Nahab, F. Tags: Stroke prevention, Infarction EDITORIALS Source Type: research

The effect of statin use in acute ischemic stroke patients treated with thrombolytic therapy
This study investigated the effects of statins for the acute ischemic stroke patients after thrombolysis on the stroke outcome considering statin intensity and time window.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Jong-Moo Park, Tae Kyoung Kim, Eui Sung Jung, Kyusik Kang, Woung-Woo Lee, Jungju Lee, Ohyun Kwon, Byung-Kun Kim Source Type: research

Association of CYP3A4*1G and CYP3A5*3 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population
Background and purpose: Previous studies have shown that common variants within CYP3A4 and CYP3A5 are associated with statin pharmacokinetics and the risk of cardiovascular disease. However, the association of variants in CYP3A4 and CYP3A5 with the prognosis of ischemic stroke remains undetermined. Therefore, we investigated this herein. Methods: Four hundred thirty-three consecutive patients with acute ischemic stroke were recruited. The outcome at the 1-year follow-up was assessed using the modified Rankin Scale (mRS).
Source: Journal of Stroke and Cerebrovascular Diseases - May 3, 2019 Category: Neurology Authors: Shuo Li, Chang-he Shi, Xin-jing Liu, Yu-sheng Li, Shao-hua Li, Bo Song, Yu-ming Xu Source Type: research